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Abstract
Objective. The anti-cyclic citrullinated peptide (anti-CCP) antibody has been increasingly used in the
field of rheumatology, and various manufacturers have developed a variety of anti-CCP assays using
mainly ELISA techniques. This study evaluated the performance of recently marketed automated
chemiluminescence enzyme immunoassays for anti-CCP.
Methods. We investigated four anti-CCP assays (Diastat anti-CCP ELISA assay, Axsym anti-CCP assay
on the Axsym system, the Architect anti-CCP assay on the Architect i2000 system and the Elecsys
anti-CCP assay on the Cobas e 411 analyzer). Samples from 64 patients with RA and 152 controls,
including patients with various autoimmune diseases, were studied. We assessed the clinical sensitivities
and specificities, and compared the qualitative and quantitative results of each anti-CCP assay.
Results. Using the manufacturers’ cut-off, diagnostic sensitivities ranged from 90.6 to 93.8% and the
specificities ranged from 85.5 to 86.8%. The areas under the curve were comparable among the different
assays, and qualitative agreements ranged from 97.2 to 99.1%. In the quantitative results, all anti-CCP
assays were significantly correlated (P<0.001), but the correlation coefficient ranged from 0.615 to 0.861.
Especially, the correlation coefficients between the automated anti-CCP assays were higher than those
between the ELISA assay (Diastat) and the automated assays.
Conclusions. The overall diagnostic performance of the automated anti-CCP assays was comparable,
and it provides reliable information on antibody levels, making them useful in monitoring disease activity.
Key words: Anti-cyclic citrullinated peptide antibody, Enzyme immunoassay, Automation.
Introduction
In 1998, Schellekens et al. [1] discovered that
anti-citrullinated peptide antibodies specific for RA bind
to antigenic determinants that contain citrulline, a
modified form of arginine produced by the action of
peptidyl-arginine deaminase. The first generation ELISA
was developed for the detection of RA-specific
anti-citrullinated peptide antibodies [2]. As peptide cycli-
zation for the generation of a peptide with a higher affin-
ity was used, this RA-specific antibody was called
the anti-cyclic citrullinated peptide (anti-CCP) antibody.
However, the first-generation anti-CCP assay had low
analytical sensitivity (ranging from 48 to 68%) [2–4], and
so a second generation anti-CCP assay was developed
using highly reactive peptides identified from dedicated
libraries of citrullinated peptides screened with RA
sera. The second-generation assay showed significant
increases in sensitivity compared with the first-genera-
tion assay [5]. Although a third-generation assay was
developed, previous comparative studies have shown
only slightly increased sensitivity [6] or no significant
improvement in comparison with that of the second
generation [7, 8].
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Currently, anti-CCP assays are helpful in various clinical
situations, such as early diagnosis of RA, diagnosing
RF-negative RA and differentiating RA and other
RF-positive arthritis RA, such as hepatitis C virus-related
arthritis or undifferentiated polyarthritis [9–13]. Liao et al.
[14] proposed to include the results of an anti-CCP assay
into the existing 1987 ACR criteria. This revised criteria
improved RA classification sensitivity, especially in early
RA. Recently, the quantitative results of anti-CCP assays
have also been investigated. Studies have shown that
higher levels of anti-CCP are related to disease progres-
sion to RA [15, 16] and the severity of RA symptoms [17].
In spite of the importance of anti-CCP quantitative results,
previous studies have evaluated various anti-CCP only
using only qualitative or diagnostic performance metrics.
In a clinical laboratory setting, testing with automated
immunoassay analysers is preferred to manual ELISA in
terms of technical simplicity, the random-access property,
its reduced labour intensity and minimal operator-
associated errors. Furthermore, automated immunoassay
analysers provide better assay accuracy and precision
[18–20]. In the present study, we evaluated the analytical
and clinical performances of four anti-CCP assays,
including two new, fully automated, random access
assays: the Architect anti-CCP assay and the Elecsys
anti-CCP assay.
Materials and methods
Patients and sample design
A total of 216 consecutive patients, examined in the rheu-
matology clinics of a single tertiary-care university hospital
from December 2008 to February 2009 and who under-
went anti-CCP testing, were enrolled in the study. The
study was approved by the ethics committee of the
Yonsei University Health System Severance Hospital.
Sixty-four patients were diagnosed with RA according
to the ACR criteria [21] and constituted the RA group
[12 males: median age 56 (range 29–67) years and 52
females: median age 52 (range 20–73) years]. The control
group consisted of 152 non-RA patients [33 males:
median age 51 (range 4–79) years and 119 females:
median age 47 (range 3–83) years]. The non-RA patients
were further classified into four groups: OA, undifferen-
tiated arthritis (UA), asymptomatic with positive RF (RFP)
and other disease (OD), according to their diagnosis.
The diagnosis of OA was based on revised ACR criteria
for OA [22], and UA was defined as arthritis that did not
fulfil the classification criteria for a definitive diagnosis,
according to the ACR criteria for RA [13, 21]. The RFP
group of 37 apparently healthy individuals presented
with only RF positivity who had negative medical histories
for rheumatic or autoimmune diseases. Among the OD
group were 48 patients with either juvenile idiopathic
arthritis (JIA) (n= 22), SS (n= 8), Behc¸et’s disease (n= 8),
SLE (n= 6), PMR (n= 2), scleroderma (n= 1) or gouty
arthritis (n= 1). All serum samples were stored at 80C
until they were assayed.
Anti-CCP antibody and RF determination
Anti-CCP was determined by one commercially available
second-generation ELISA (Diastat anti-CCP; Axis-Shield
Diagnostics, Dundee, UK) and the following three com-
mercially available automated EIAs: the Architect
anti-CCP assay on the Architect i2000 system (Abbott
Laboratories, Abbott Park, IL, USA), the Axsym anti-CCP
assay on the Axsym system (Abbott Laboratories) and the
Elecsys anti-CCP assay on the Cobas e 411 Analyzer
(Roche Diagnostics, Mannheim, Germany). The proce-
dures were conducted according to the manufacturer’s
recommendations. Key characteristics of each method
are shown in Table 1. RF was determined by nephelome-
try on an IMMAGE 800 (Beckman-Coulter, Fullerton,
CA, USA) according to the manufacturer’s instruction.
A positive result was recorded when RF concentration
was >20 IU/ml.
Statistical analysis
The k statistics, receiver operating characteristic (ROC)
analysis, Spearman rank correlations and Passing–
Bablok analysis were performed using the statistical soft-
ware packages Analyze-It for Microsoft Excel (version
2.12) and SPSS for Windows. The sensitivity and specifi-
city of each method were calculated using the manufac-
turer’s cut-off and the optimal cut-off obtained by ROC
curve analysis.
Table 1 Characteristics of the four anti-CCP assays evaluated in this study
Reagent Diastat Architect Axsym Elecsys
Manufacturer Axis-Shield
Diagnostics
Abbott
Laboratories
Abbott
Laboratories
Roche
Diagnostics
Technique ELISA CMIA MEIA ECLIA
No. of calibrators 5 6 6 2
Range of calibrator, U/ml 0–100 0–200 0–200 0–200
Measuring range, U/ml 0–100 <0.5–200 <1.0–200 <7–1000
Reference range, U/ml 0.05–3.8 <0.5–2.5 <1.0–2.9 NA
Cut-off level, U/ml 5 5 5 17
CMIA: chemiluminescent microparticle immunoassay; MEIA: microparticle EIA; ECLIA: electrochemiluminescent immunoassay.
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Results
Comparison of diagnostic performance
Using the cut-off values proposed by the manufacturers,
60 (93.9%), 59 (92.2%), 60 (93.8%) and 58 (90.6%) of the
64 RA patients and 22 (14.5%), 22 (14.5%), 20 (13.2%)
and 20 (13.2%) of the 152 non-RA patients tested positive
on the Diastat, Architect, Axsym and Elecsys assays,
respectively (Table 2). Among the non-RA patients, 2/44
OA, 9/37 UA, 7/22 JIA, 1/8 Behc¸et’s disease, 2/8 SS and
1/1 gouty arthritis patients showed a positive reaction to
one or more of the assays. Distributions of anti-CCP con-
centrations according to disease category (RA, OA, UA,
RFP and OD) for each assay are shown in Fig. 1.
The overall correlation of the qualitative results of the
four anti-CCP assays is shown in Table 3. The agreement
between the qualitative results of the Diastat, Architect,
Axsym and Elecsys assays ranged from 97.2 to 99.1%.
The k coefficients of each assay were all over 0.940. Eight
discrepant results among the four different anti-CCP
assays are shown in Table 4. Irrespective of clinical diag-
nosis, the Diastat anti-CCP assay showed more positive
results (6/8) than did the Architect (5/8), Axsym (4/8) and
Elecsys (2/8) assays.
The areas under the curve (AUCs) were 0.903, 0.917,
0.914 and 0.907 for Diastat, Architect, Axsym and
Elecsys, respectively (Table 5). We compared the AUCs
of all other methods with that of the highest AUC (the
Architect assay) and found no significant differences.
In the case of RF, the AUC was 0.627, which was signi-
ficantly different from all other anti-CCP assays
(P< 0.0001).
The diagnostic sensitivity and specificity of each assay
are shown in Table 5. At the manufacturer’s cut-offs, sen-
sitivities ranged from 90.6 to 93.8%, and specificities
ranged from 85.5 to 86.8%. Optimal cut-off values were
estimated based on the highest sum of sensitivity and
specificity, and diagnostic performance was calculated
for each assay at the optimal cut-off. Especially with the
Elecsys anti-CCP assay, the value of the optimal cut-off
was lower than the manufacturer’s cut-off, and this
optimal cut-off improved sensitivity from 90.6 to 92.2%
without important losses in specificity.
Comparison of quantitative results
The correlations between the quantitative results are
shown in Fig. 2. All anti-CCP assays were well correlated
(P< 0.001), but the Spearman correlation coefficient (rs)
between the four assays ranged from 0.615 to 0.861. The
best correlation was observed between the Architect and
Axsym assays, with a correlation coefficient of 0.886,
whereas the correlation between the Diastat and Axsym
was the worst (rs= 0.615). Interestingly, the correlation
between the automated anti-CCP assays (Architect,
Axsym and Elecsys) was higher than with the manual
ELISA assay (Diastat).
Discussion
Since anti-CCP ELISA was introduced in 2000, it has been
increasingly used as a diagnostic test for RA. With the
development of the second-generation anti-CCP ELISA,
analytical sensitivity significantly increased while main-
taining high specificity. A recent meta-analysis reported
the sensitivity and specificity of the anti-CCP assay for
RA as 67 and 95%, respectively [23]. Besides its use as
a diagnostic aid for RA, the presence of anti-CCP is pre-
dictive for RA development [24, 25], and the level
of anti-CCP is associated with the development of bone
erosion in RA [26, 27]. However, the correlation between
the reduction of anti-CCP concentration and clinical
responses to RA treatment is controversial [28, 29].
Numerous manufacturers produce anti-CCP assays,
mainly using the ELISA format. However, an international
reference serum of anti-CCP assays has not been pre-
pared. Each manufacturer uses its own calibrators
Table 2 Number of positive anti-CCPa and RF results in RA and non-RA patients according to assay
Total, n
Positive, n (%)
Diastat Architect Axsym Elecsys RF
RA 64 60 (93.8) 59 (92.2) 60 (93.8) 58. (90.6) 44 (68.8)
Non-RA 152 22 (14.5) 22 (14.5) 20 (13.2) 20 (13.2) 68 (44.7)
OA 44 2 (4.5) 2 (4.5) 1 (2.3) 2 (4.5) 5 (11.4)
UA 23 9 (39.1) 8 (34.8) 8 (34.8) 7 (30.4) 9 (39.1)
RFP 37 2 (5.4) 2 (5.4) 2 (5.4) 2 (5.4) 37 (100)
JIA 22 6 (27.3) 6 (27.3) 6 (27.3) 6 (27.3) 5 (22.7)
Behc¸et’s disease 8 1 (12.5) 1 (12.5) 1 (12.5) 1 (12.5) 1 (12.5)
SS 8 1 (12.5) 2 (25.0) 1 (12.5) 1 (12.5) 5 (62.5)
SLE 6 0 (0) 0 (0) 0 (0) 0 (0) 5 (83.3)
PMR 2 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Gouty arthritis 1 1 (100) 1 (100) 1 (100) 1 (100) 1 (100)
Scleroderma 1 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
aAt manufacturer’s cut-off.
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Fig. 1 Scatter plots of anti-CCP level according to disease category. The lines indicate the manufacturers’ cut-off
values. OD includes JIA; SS, Behc¸et’s disease, SLE, PMR, scleroderma and gouty arthritis.
Table 4 Discrepant results between the four anti-CCP assaysa
No. Sex/age
Results of anti-CCP (measured value, U/ml)
Clinical
diagnosisDiastat Architect Axsym Elecsys
1 F/57 Pos (14.5) Pos (10.8) Pos (11.7) Neg (14.7) RA
2 F/47 Pos (5.4) Neg (4.3) Pos (5.2) Neg (9.4) RA
3 F/49 Pos (7.3) Neg (2.5) Neg (1.6) Neg (<7.0) UA
4 F/35 Pos (16.3) Pos (11.3) Pos (15.5) Neg (13.6) UA
5 F/14 Pos (9.0) Neg (2.6) Pos (6.0) Neg (<7.0) JIA
6 M/15 Neg (1.0) Pos (16.3) Neg (2.7) Pos (30.4) JIA
7 F/53 Pos (12.0) Pos (5.1) Neg (2.8) Pos (39.3) OA
8 F/39 Neg (3.5) Pos (6.6) Neg (2.9) Neg (<7.0) SS
aAt manufacturer’s cut-off.
Table 3 Agreement and k statistics between the anti-CCP assays
Assay
i statistics and percent agreement between two anti-CCPs
(no. of identical results/total)
Diastat Architect Axsym Elecsys
Diastat – 0.951 0.980 0.940
Architect 97.7 (211/216) – 0.950 0.970
Axsym 99.1 (214/216) 97.7 (211/216) – 0.940
Elecsys 97.2 (210/216) 98.6 (213/216) 97.2 (210/216) –
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and control materials without standardization between
assays. Several previous studies have compared the
technical and diagnostic performance of anti-CCP
assays produced by diverse manufacturers. Although
the overall diagnostic performance of anti-CCP assays
was comparable across the different assays, they recom-
mended careful selection of methods in a clinical labora-
tory setting [7, 8, 18, 30]. Recently, novel anti-CCP assays
using automated platforms have been developed.
Automated immunoassay analysers offer great advan-
tages over traditional ELISA (especially for high-volume
hospital laboratories), such as improved precision, relia-
bility, technical simplicity, short turnaround time and
high-speed throughput. Because previous evaluations
were limited to aspects of qualitative and diagnostic per-
formance for each anti-CCP assay, we decided to assess
the diagnostic performance and quantitative results of
four anti-CCP assays. One anti-CCP assay used the
ELISA methodology (Diastat), whereas the other three
(Architect, Axsym and Elecsys) were available in auto-
mated immunoassay analysers using CMIA, MEIA and
ECLIA, respectively.
The overall agreement between the qualitative results of
the four anti-CCP assays was good. The best agreement
(99.1%) was observed between Diastat and Axsym,
and the worst agreements (97.2%) were observed
between Diastat and Elecsys and Axsym and Elecsys.
The difference between the best and worst agreement
was 1.9%, which is minimal.
Regarding diagnostic performance, the Architect
assays showed the highest AUC (0.917). However, the
other three anti-CCP assays showed similar perfor-
mances when compared with the Architect assay. The
AUC was not statistically different among the assays eval-
uated, suggesting that the diagnostic performances of
the four anti-CCP assays were comparable. At the man-
ufacturer’s cut-off, diagnostic sensitivities and specifici-
ties ranged from 90.6 to 93.8% and from 85.5 to 86.8%,
respectively. Previous meta-analysis has presented the
sensitivities and the specificities of second-generation
anti-CCP assays as 68% (range 39–93%) and 95%
(range 81–100%), respectively [31]. In this study, the clin-
icians knew the anti-CCP results of enrolled patients
and thereafter confirmed the final diagnosis, a study
design that would probably generate higher sensitivities
than those of previously published reports. However,
anti-CCP assays are already widely used in clinics and
so this study design reflects real everyday rheumatology
practice.
The correlation between the quantitative results of the
four anti-CCP assays was good (P< 0.001). Especially,
the correlation coefficients (range 0.861–0.886) between
three automated anti-CCP assays were higher than
that of the manual ELISA and automated assays (range
0.615–0.788). The measurement ranges of the four
anti-CCP assays were different from each other. The
Diastat anti-CCP assay showed the narrowest measuring
range (0–100 U/ml), with the results of 47/82 (57.3%)
anti-CCP-positive patients (>5 U/ml) exceeding the mea-
suring range (>100 U/ml). Contrarily, the Elecsys anti-CCP
assay showed the widest measuring range (<7–1000 U/ml),
with only 12/78 (15.4%) anti-CCP-positive patients
(>17 U/ml) exceeding the measuring range (>1000 U/ml).
This may be important in quantitative measurement of
anti-CCP levels and in the clinical application of the quan-
titative results related to disease progression or treatment
outcome.
The lack of interchangeability of the various anti-CCP
assays may prevent objective judgement and unbiased
comparison of the results of previous studies. Clinicians
and researchers should be alerted to the fact that
results from the various anti-CCP assays now available
could differ, especially quantitatively. Although a limited
number of batches of reagent and calibrators were
used, our study showed that the quantitative results of
one automated assay could be interchangeably converted
to the results of the other two automated assays using
the correlation equation. International standardization or
harmonization of anti-CCP assays should be achieved
as soon as possible.
Table 5 Clinical diagnostic performances of the four anti-CCP assays and RF
Diastat Architect Axsym Elecsys RF
ROC AUC (95% CI) 0.903 (0.855, 0.951) 0.917 (0.878, 0.956) 0.914 (0.872, 0.956) 0.907 (0.864, 0.951) 0.627 (0.546, 0.707)
Manufacturer’s cut-off 5.0 5.0 5.0 17.0 20.0
Sensitivity (95% CI) 93.8 (84.8, 98.3) 92.2 (82.7, 97.4) 93.8 (84.8, 98.3) 90.6 (80.7, 96.5) 68.8 (55.9, 79.8)
Specificity (95% CI) 85.5 (78.9, 90.7) 85.5 (78.9, 90.7) 86.8 (80.4, 91.8) 86.8 (80.4, 91.8) 57.2 (49.0, 65.2)
Positive predictive
value, %
73.2 72.8 75.0 74.4 40.4
Negative predictive
value, %
97.0 96.3 97.1 95.7 81.3
Optimal cut-off 3.6 5.1 3.5 13.6 22.5
Sensitivity (95% CI) 93.8 (84.8, 98.3) 92.2 (82.7, 97.4) 93.8 (84.8, 98.3) 92.2 (82.7, 97.4) 67.2 (54.3, 78.4)
Specificity (95% CI) 85.5 (78.9, 90.7) 86.2 (79.7, 91.2) 86.8 (80.4, 91.8) 86.2 (79.7, 91.2) 59.9 (51.6, 67.7)
Positive predictive
value, %
73.2 73.8 75.0 74.1 41.3
Negative predictive
value, %
97.0 96.3 97.1 96.3 81.3
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Rheumatology key messages
. Quantitative value of anti-CCP could differ accord-
ing to assay format.
. Automated anti-CCP assays provide more reliable
quantitative results.
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